Illumina (ILMN) Shares are Up 1.3%

Illumina (ILMN) : Traders are bullish on Illumina (ILMN) as it has outperformed the S&P 500 by a wide margin of 8.78% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.13%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.3% in the last 1 week, and is up 8.2% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 4.58% and the 50-Day Moving Average is 7.34%.The 200 Day SMA reached 15.24%

Illumina

Illumina (NASDAQ:ILMN): After opening at $177.44, the stock dipped to an intraday low of $176.71 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $182.61 and the buying power remained strong till the end. The stock closed at $181.66 for the day, a gain of 2.89% for the day session. The total traded volume was 1,283,304. The stocks close on the previous trading day was $181.66.

Illumina (ILMN) : The highest level Illumina (ILMN) is projected to reach is $200 for the short term and the lowest estimate is at $115. The consolidated price target from 11 rating analysts who initiate coverage on the stock is $156.46 and the possibility the share price can swing is $24.32.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.